Antibody cocktail for Covid emerges as ray of hope, but cost makes it prohibitive for most
Akanksha Chawala, a critical care pulmonologist at Apollo hospital in Delhi, said she had used the therapy in just two patients but the results had been extraordinary.
Share Via Email
| A+A A-
An artist paints No mask No Entry graffiti at Chennai Central Railway station. (File Photo | Martin Louis, EPS)
Express News Service
NEW DELHI: A month after an antibody cocktail was approved for treating mild to moderate Covid-19 in high-risk patients in India, some leading private hospitals in the country have said that they have achieved remarkable results with its usage so far.
Bharat Biotech on Friday said it was pursuing the FDA advice and full approval, when granted to COVAXIN, would be the first for any Indian vaccine maker.
URL copied
Covaxin phase 3 full trial results will be made public in July.
Covaxin phase 3 full trial results will be made public in July, Bharat Biotech informed on Wendesday. Covaxin is one of the three vaccines other than Oxford s Covishield and Russia s Sputnik V, that are being administered in India. It is critical to understand and further emphasise the phase-3 data will first be submitted to Central Drugs Standard Control (CDSCO) followed by peer-reviewed journals, with a timeline of 3 months for publication, and as communicated earlier COVAXIN phase 3 results full trial data will be made public during July. Once data from the final analysis of phase III studies are available, Bharat Biotech will apply for full licensure for COVAXIN, Bharat Biotech informed ANI.
A medical worker displays a vial of the Covaxin vaccine. | Indranil Mukherjee/AFP
Bharat Biotech, the manufacturer of coronavirus vaccine Covaxin, on Wednesday criticised a recent study that found that its jab produced significantly fewer antibodies than Covishield.
In a statement, the Hyderabad-based company claimed that the study “had lots of flaws”, ANI reported.
The company also said that the phase 3 trial data for Covaxin will be made public in July. The indigenously developed vaccine was granted an emergency use authorisation in January – despite there being no phase 3 trial data. The company had then said it would submit efficacy results by March.